UA98783C2 - Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission - Google Patents
Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmissionInfo
- Publication number
- UA98783C2 UA98783C2 UAA200911475A UAA200911475A UA98783C2 UA 98783 C2 UA98783 C2 UA 98783C2 UA A200911475 A UAA200911475 A UA A200911475A UA A200911475 A UAA200911475 A UA A200911475A UA 98783 C2 UA98783 C2 UA 98783C2
- Authority
- UA
- Ukraine
- Prior art keywords
- modulators
- disubstituted
- phenylpyrrolidines
- cortical
- catecholaminergic neurotransmission
- Prior art date
Links
- VDQQJMHXZCMNMU-UHFFFAOYSA-N 1-phenylpyrrolidine Chemical class C1CCCN1C1=CC=CC=C1 VDQQJMHXZCMNMU-UHFFFAOYSA-N 0.000 title 1
- 230000000768 catecholaminergic effect Effects 0.000 title 1
- 230000001054 cortical effect Effects 0.000 title 1
- 230000005062 synaptic transmission Effects 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- VXGOBKMZBNJSTA-UHFFFAOYSA-N 1-hydroxy-2-phenylpyrrolidine Chemical class ON1CCCC1C1=CC=CC=C1 VXGOBKMZBNJSTA-UHFFFAOYSA-N 0.000 abstract 1
- 150000003943 catecholamines Chemical class 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 210000005171 mammalian brain Anatomy 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0701387 | 2007-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA98783C2 true UA98783C2 (en) | 2012-06-25 |
Family
ID=39743744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200911475A UA98783C2 (en) | 2007-06-05 | 2008-06-04 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8188301B2 (enExample) |
| EP (1) | EP2155671B8 (enExample) |
| JP (1) | JP5444535B2 (enExample) |
| KR (1) | KR20100038295A (enExample) |
| CN (1) | CN101808987A (enExample) |
| AU (1) | AU2008258599B2 (enExample) |
| BR (1) | BRPI0812740A2 (enExample) |
| CA (1) | CA2690091A1 (enExample) |
| CO (1) | CO6251288A2 (enExample) |
| IL (1) | IL202045A0 (enExample) |
| MX (1) | MX2009012787A (enExample) |
| NZ (1) | NZ581364A (enExample) |
| RU (1) | RU2471781C2 (enExample) |
| UA (1) | UA98783C2 (enExample) |
| WO (1) | WO2008148801A2 (enExample) |
| ZA (1) | ZA200908592B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101808987A (zh) | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
| WO2010058018A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| US8586572B2 (en) | 2008-11-24 | 2013-11-19 | Integrative Research Laboratories Sweden Ab | 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| US20110257148A1 (en) * | 2008-11-24 | 2011-10-20 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| AR074755A1 (es) * | 2008-12-16 | 2011-02-09 | Astrazeneca Ab | Derivados cuaternarios de piperidina y sus usos |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| US10428019B2 (en) * | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| CN107646031B (zh) * | 2015-05-20 | 2020-11-17 | 综合研究实验室瑞典股份公司 | 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物 |
| JP6770005B2 (ja) | 2016-02-10 | 2020-10-14 | 住友化学株式会社 | １−メチルピロリジン−３−オールの製造方法 |
| DK3625213T3 (da) * | 2017-05-19 | 2023-04-24 | Integrative Res Laboratories Sweden Ab | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2878264A (en) * | 1959-03-17 | Substituted amino alcohols | ||
| DE1144279B (de) | 1957-09-26 | 1963-02-28 | Robins Co Inc A H | Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen |
| US3118907A (en) * | 1961-08-14 | 1964-01-21 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
| BE704683A (enExample) | 1966-11-07 | 1968-02-15 | ||
| US3635982A (en) | 1969-04-08 | 1972-01-18 | American Home Prod | Amino-substituted-quinoxalinyloxazolidines and -oxazines |
| US5128362A (en) * | 1988-01-15 | 1992-07-07 | Abbott Laboratories | 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes |
| DE3802175A1 (de) | 1988-01-26 | 1989-08-03 | Hoechst Ag | N-phenylbenzamide und n-phenylbenzamidoxime, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel |
| DE3835291A1 (de) * | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
| US5444083A (en) * | 1989-02-03 | 1995-08-22 | Eisai Co., Ltd. | Pyrrolidine compound and pharmaceutical use |
| EP0641320B1 (en) * | 1991-04-17 | 2001-05-30 | PHARMACIA & UPJOHN COMPANY | Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists |
| EP0586229A1 (en) * | 1992-09-01 | 1994-03-09 | Zeneca Limited | 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors |
| US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| EP1098892A1 (en) | 1998-07-20 | 2001-05-16 | MERCK PATENT GmbH | Biphenyl derivatives |
| US20020169155A1 (en) * | 1998-09-04 | 2002-11-14 | Millennium Pharmaceuticals, Inc. | Chemokine receptor anagonists and methods of use therefor |
| US7271176B2 (en) * | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| DE19840611A1 (de) * | 1998-09-05 | 2000-03-09 | Klaus Wanner | GABA-uptake-Inhibitoren mit Pyrrolidinstruktur |
| AU5273100A (en) | 1999-05-17 | 2000-12-05 | Foxboro Company, The | Methods and apparatus for control configuration with versioning, security, composite blocks, edit selection, object swapping, formulaic values and other aspects |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| US7547693B2 (en) * | 2003-09-22 | 2009-06-16 | Banyu Pharmaceutical Co. Ltd. | Piperidine derivative |
| SE0401465D0 (sv) | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| US7700587B2 (en) * | 2004-09-07 | 2010-04-20 | Florida A&M University | Haloperidol analogs |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| WO2006117669A1 (en) | 2005-05-03 | 2006-11-09 | Pfizer Inc. | Amide resorcinol compounds |
| WO2007053145A1 (en) | 2005-11-04 | 2007-05-10 | Florida A & M University | Haloperidol analogs |
| CN101341135B (zh) | 2005-12-21 | 2013-08-14 | 詹森药业有限公司 | 治疗mch-1介导的疾病的取代的吡嗪酮衍生物 |
| CN101808987A (zh) | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
| MX2009012716A (es) | 2007-06-05 | 2009-12-14 | Nsab Af Neurosearch Sweden Ab | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. |
-
2008
- 2008-06-04 CN CN200880018820A patent/CN101808987A/zh active Pending
- 2008-06-04 JP JP2010510783A patent/JP5444535B2/ja not_active Expired - Fee Related
- 2008-06-04 BR BRPI0812740A patent/BRPI0812740A2/pt not_active IP Right Cessation
- 2008-06-04 WO PCT/EP2008/056915 patent/WO2008148801A2/en not_active Ceased
- 2008-06-04 CA CA2690091A patent/CA2690091A1/en not_active Abandoned
- 2008-06-04 AU AU2008258599A patent/AU2008258599B2/en not_active Expired - Fee Related
- 2008-06-04 KR KR1020097025393A patent/KR20100038295A/ko not_active Withdrawn
- 2008-06-04 US US12/663,223 patent/US8188301B2/en not_active Expired - Fee Related
- 2008-06-04 UA UAA200911475A patent/UA98783C2/ru unknown
- 2008-06-04 NZ NZ581364A patent/NZ581364A/en not_active IP Right Cessation
- 2008-06-04 MX MX2009012787A patent/MX2009012787A/es active IP Right Grant
- 2008-06-04 RU RU2009143104/04A patent/RU2471781C2/ru not_active IP Right Cessation
- 2008-06-04 EP EP08760496.3A patent/EP2155671B8/en not_active Not-in-force
-
2009
- 2009-11-11 IL IL202045A patent/IL202045A0/en unknown
- 2009-12-03 ZA ZA2009/08592A patent/ZA200908592B/en unknown
- 2009-12-18 CO CO09145364A patent/CO6251288A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2471781C2 (ru) | 2013-01-10 |
| MX2009012787A (es) | 2009-12-15 |
| NZ581364A (en) | 2011-10-28 |
| BRPI0812740A2 (pt) | 2016-07-19 |
| AU2008258599A1 (en) | 2008-12-11 |
| US20100179211A1 (en) | 2010-07-15 |
| CN101808987A (zh) | 2010-08-18 |
| ZA200908592B (en) | 2011-02-23 |
| JP5444535B2 (ja) | 2014-03-19 |
| IL202045A0 (en) | 2010-06-16 |
| EP2155671B8 (en) | 2018-02-21 |
| KR20100038295A (ko) | 2010-04-14 |
| RU2009143104A (ru) | 2011-07-20 |
| WO2008148801A2 (en) | 2008-12-11 |
| EP2155671A2 (en) | 2010-02-24 |
| US8188301B2 (en) | 2012-05-29 |
| CA2690091A1 (en) | 2008-12-11 |
| EP2155671B1 (en) | 2017-12-20 |
| AU2008258599B2 (en) | 2013-06-13 |
| CO6251288A2 (es) | 2011-02-21 |
| JP2010529081A (ja) | 2010-08-26 |
| WO2008148801A8 (en) | 2009-12-10 |
| WO2008148801A3 (en) | 2009-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA98783C2 (en) | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MX2012004548A (es) | Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central. | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| MY157192A (en) | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands | |
| MY189750A (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| UY32967A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina | |
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| CL2011000488A1 (es) | Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus. | |
| CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
| EP2498609A4 (en) | SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | |
| MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| UA104152C2 (ru) | Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии | |
| CL2012001031A1 (es) | Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros. | |
| MX2009012716A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical. | |
| CL2009001282A1 (es) | Compuestos derivados de pirrolidin amidas sustituidas, moduladores del receptor de histamina h3; composicion farmaceutica que los contiene; y su uso para el tratamiento de enfermedades tales como demencia, alzheimer, disfuncion cognitiva, trastorno de la memoria, trastorno de aprendizaje, deficit atencional, entre otras. | |
| WO2011014520A3 (en) | Compounds and compositions as modulators of gpr119 activity | |
| TW200642690A (en) | Composition for treating central nervous system disorders |